Enterprise Value

1.15B

Cash

392.5M

Avg Qtr Burn

-40.71M

Short % of Float

26.10%

Insider Ownership

4.18%

Institutional Own.

-

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Azenosertib (ZN-c3) (oral inhibitor of WEE1) w/ chemo Details
Ovarian cancer, Cancer, Platinum-resistant ovarian cancer

Phase 3

Initiation

Phase 2

Interim update

ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details
Cancer, relapsed or refractory light chain amyloidosis

Phase 1/2

Interim update

Phase 1/2

Update

ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details
Non-Hodgkin lymphoma, Acute myeloid leukemia, Cancer

Phase 1b

Data readout

Failed

Discontinued

Failed

Discontinued